Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development and manufacture of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its partners.
Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS.
PolyTherics, Antitope, PacificGMP and TCRS have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.
Revenue (FY, 2017)
Gross profit (FY, 2017)
Gross profit margin (FY, 2017), %
Net income (FY, 2017)
EBITDA (FY, 2017)
EBIT (FY, 2017)
Market capitalization (31-Oct-2017)
Closing share price (31-Oct-2017)